Comparative Pharmacology
Head-to-head clinical analysis: ARDUAN versus ATRACURIUM BESYLATE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARDUAN versus ATRACURIUM BESYLATE PRESERVATIVE FREE.
ARDUAN vs ATRACURIUM BESYLATE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nondepolarizing neuromuscular blocking agent; competitively blocks acetylcholine at nicotinic receptors at the motor end-plate.
Nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at nicotinic cholinergic receptors at the neuromuscular junction, preventing depolarization and muscle contraction. Degraded via Hofmann elimination (non-enzymatic) and ester hydrolysis.
Initial IV bolus of 0.08 mg/kg followed by incremental doses of 0.01 mg/kg to maintain neuromuscular blockade
0.4-0.5 mg/kg IV bolus for intubation; maintenance: 0.08-0.1 mg/kg IV every 15-25 min or continuous infusion 5-10 mcg/kg/min
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.9 hours); prolonged in renal impairment
Terminal elimination half-life of atracurium is approximately 20 minutes (range 15-35 min) in healthy adults; clinically, this short half-life correlates with rapid spontaneous recovery without the need for reversal agents, though prolonged in hypothermia or acidosis.
Primarily renal (60-70% unchanged drug); biliary/fecal (20-30%)
Primarily via Hofmann elimination (non-enzymatic degradation) and ester hydrolysis; renal excretion accounts for less than 10% unchanged, with biliary/fecal elimination minimal. Approximately 40% as laudanosine and other metabolites via urine, with laudanosine further metabolized and renally excreted.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker